We got a nice bump! // I'm inclined to buy more here- CENX Century Aluminum Company $12.48-0.43(-3.29%)5:14 AM 03/06/23
I see AA is down a stick. probably should of kept my mouth shut... There actually is a reason and it may pause this cyclical stuff.. Iron ore, industrial metals slide on China’s modest new growth target
SNAP is stirring. Option activity is high. U.S. factory orders tumbled -1.6% in January » 10:20 $ECON Bad News is good news,
SP500 S&P 500 Index-- Just from memory 4,080 was a place The Lizard King twice scored from. I would say there is something about that number // $4,071.82 +26.18
Van informed me that Bowlero was a SPAC. I was surprised. We must add this to our growing list of " spacs that made it " I think $5 +over $10 should be our metric.... BOWL Bowlero Corp. $16.09
by Brian Sozzi, Yahoo Finance's executive editor. I think the market has the case of the blahs. While I really enjoyed watching Salesforce and C3.ai shares explode higher post earnings last week, hot movers along these lines have been too few and far between (in either direction) in recent weeks. But if you take a step back and level set the stock market today, the muted action kind of makes a great deal of sense. Investors are facing a fresh dilemma — call it paralysis by analysis amid all the incoming data flying in. On the one hand, we have hot retail sales and inflation reports from the government — both calling into question whether the Federal Reserve is moving fast enough to squash inflation. On the other end of the spectrum, the jobs market continues to be solid (as probably seen in this week's jobs report). Yet, when you look at fourth quarter earnings (and conference calls) from Best Buy, Home Depot, Target and other retailers, you will see consumer weakness in big ticket merchandise. Dig into Target's earnings, and you will see a shopper trading down to cheaper private label goods because they are less inflationary and they just got laid off by a tech company. Taken together, this is a confusing time to be an investor – something market maven Keith Lerner at Truist captures in a new note he sent me: "The recent action is very much aligned with a key market dilemma we have been highlighting: If the economy stays stronger, as we have seen recently, Fed policy is set to remain tighter, and this will weigh on market valuations. Or, instead, if the economy weakens, this will pressure profits. Neither of these outcomes are favorable for premium market valuations." In other words, Mr. Market doesn't know what he wants! {--> I would say that's a no win situation! a bit more than lack of wants... but yes.} And if you think all the bad news of any kind is priced into stocks, Lerner adds these considerations: "For perspective, the S&P 500’s forward P/E of 17.6x is still slightly above the 10-year average of 17.2x, and that’s in the context of a high degree of uncertainty around economic growth, inflation, and earnings. Forward earnings estimates are hovering near a 52- week low, and downside risks remain. The 1-year U.S. Treasury yield has jumped above 5% for the first time since 2007, and the 10-year U.S. Treasury yield, which is hovering around 4%, is nearly double the average of the past decade." <<<<>>>> Yea yea yea but there are other things to consider such as---> what if we are ina new era for PE's? I think we are-- 20 is the new 17.
As far as I know this is The #1 SPAC-! MoonLake Immunotherapeutics (MLTX) NasdaqCM - NasdaqCM Real Time Price. Currency in USD Follow 22.68+0.67(+3.04%) As of 10:55AM EST.
Athabaska ( ATH on TSX ) is gradually breaking out. Fake out sell off on open. I sold most of my "extra" shares at $3.24 because my position was way above norm and growing. There was a large sell order at $3.25 but the stock blew right through it.
Cantor On MoonLake Immunotherapeutics - Initiates On Inexpensive Valuation, Strong Catalyst Path February 14, 2023 MLTX +2.91% Cantor Fitzgerald has initiated coverage on MoonLake Immunotherapeutics AG (NASDAQ:MLTX) with an Overweight rating and a price target of $23. MoonLake's lead program Sonelokimab or SLK (IL-17A & IL-17F nanobody), is currently in Phase 2 trials in Hidradenitis Suppurativa (HS-severe skin disease) and Psoriatic Arthritis (PsA). A more than $5 billion opportunity for SLK in HS is the primary driver of the analyst's bullish view. Also See:HC Wainwright Starts Coverage On This 'Best-In-Class Agent For Inflammatory Disorders. After recent positive phase 3 trials from competitor IL-17 injectables, Novartis AG's (NYSE:NVS) Cosentyx and UCB SA's (OTC:UCBJY) (OTC:UCBJF) Bimekizumab raise the analyst's confidence that SLK will work in HS and will likely raise the efficacy bar. Approval of IL-17 injectables over the next few years will significantly expand the HS market, and SLK could be a ~$1.5 billion drug. SLK is also de-risked in PsA. In September, FDA signed off Phase 2 study of sonelokimab for active psoriatic arthritis.